3-Hz Postural Tremor in MSA-C and SCA: Revisiting an Old but Underestimated Cerebellar Sign by Posturography

2020 ◽  
Author(s):  
Xiaodi Li ◽  
Xiao Lv ◽  
Churong Liu ◽  
Jinlong Ye ◽  
Yan Xu ◽  
...  
Author(s):  
Aysegul Gunduz ◽  
Ayse Cigdem Aktuglu-Zeybek ◽  
Damla Tezer ◽  
Ece Oge Enver ◽  
Tanyel Zubarioglu ◽  
...  

2019 ◽  
Vol 49 (8) ◽  
pp. 1199-1216
Author(s):  
Justin W. L. Keogh ◽  
Sinead O’Reilly ◽  
Ethan O’Brien ◽  
Steven Morrison ◽  
Justin J. Kavanagh

Motor Control ◽  
2000 ◽  
Vol 4 (3) ◽  
pp. 293-315 ◽  
Author(s):  
Steven Morrison ◽  
Karl M. Newell

1993 ◽  
Vol 16 (3) ◽  
pp. 244-250 ◽  
Author(s):  
Michael P. Caligiuri ◽  
James B. Lohr
Keyword(s):  

2009 ◽  
Vol 120 (5) ◽  
pp. 1020-1029 ◽  
Author(s):  
M.E. Héroux ◽  
G. Pari ◽  
K.E. Norman

1978 ◽  
pp. 441-446 ◽  
Author(s):  
P. MARTINELLI ◽  
P. PAZZAGLIA ◽  
P. MONTAGNA ◽  
P. TINUPER ◽  
G. MORETTO ◽  
...  

2020 ◽  
pp. 55-58
Author(s):  
Fuyuko Sasaki ◽  
Yasushi Shimo ◽  
Nobutaka Hattori

A 67-year-old, right-handed man had a 7-year history of right-dominant, severe medication-refractory resting and action-postural tremor, rigidity, bradykinesia, and impairment of postural reflexes, with his symptoms poorly responsive to oral antiparkinsonian medication. His parkinsonian symptoms with the exception of tremor responded to levodopa infusion. His most bothersome symptom was tremor, and implantation of a left subthalamic nucleus (STN) deep brain stimulation (DBS) lead was pursued with possible posterior subthalamic area (PSA) DBS if the tremor suppression by STN was not intraoperatively sufficient. Ultimately, the STN DBS lead provided reasonable tremor suppression during the operation, and there was no need for PSA DBS. After the surgery, his tremor and other parkinsonian symptoms were well-controlled. This case highlights that unilateral STN DBS is a reasonable indication for medication-refractory parkinsonian tremor with significant laterality of bothersome symptoms, although other options may also be considered.


2007 ◽  
Vol 55 (4) ◽  
pp. 393 ◽  
Author(s):  
OliverP Gautschi ◽  
Dieter Cadosch ◽  
Rene Zellweger
Keyword(s):  

Neurology ◽  
2019 ◽  
Vol 93 (24) ◽  
pp. e2284-e2293 ◽  
Author(s):  
Casey H. Halpern ◽  
Veronica Santini ◽  
Nir Lipsman ◽  
Andres M. Lozano ◽  
Michael L. Schwartz ◽  
...  

ObjectiveTo test the hypothesis that transcranial magnetic resonance–guided focused ultrasound (tcMRgFUS) thalamotomy is effective, durable, and safe for patients with medication-refractory essential tremor (ET), we assessed clinical outcomes at 3-year follow-up of a controlled multicenter prospective trial.MethodsOutcomes were based on the Clinical Rating Scale for Tremor, including hand combined tremor–motor (scale of 0–32), functional disability (scale of 0–32), and postural tremor (scale of 0–4) scores, and total scores from the Quality of Life in Essential Tremor Questionnaire (scale of 0–100). Scores at 36 months were compared with baseline and at 6 months after treatment to assess for efficacy and durability. Adverse events were also reported.ResultsMeasured scores remained improved from baseline to 36 months (all p < 0.0001). Range of improvement from baseline was 38%–50% in hand tremor, 43%–56% in disability, 50%–75% in postural tremor, and 27%–42% in quality of life. When compared to scores at 6 months, median scores increased for hand tremor (95% confidence interval [CI] 0–2, p = 0.0098) and disability (95% CI 1–4, p = 0.0001). During the third follow-up year, all previously noted adverse events remained mild or moderate, none worsened, 2 resolved, and no new adverse events occurred.ConclusionsResults at 3 years after unilateral tcMRgFUS thalamotomy for ET show continued benefit, and no progressive or delayed complications. Patients may experience mild degradation in some treatment metrics by 3 years, though improvement from baseline remains significant.Clinicaltrials.gov identifierNCT01827904.Classification of evidenceThis study provides Class IV evidence that for patients with severe ET, unilateral tcMRgFUS thalamotomy provides durable benefit after 3 years.


Sign in / Sign up

Export Citation Format

Share Document